# Resource Summary Report

Generated by dkNET on Aug 13, 2026

## NK-92

RRID:CVCL_2142
Type: Cell Line

### Proper Citation

RRID:CVCL_2142

### Cell Line Information

**URL:** https://web.expasy.org/cellosaurus/CVCL_2142

**Proper Citation:** RRID:CVCL_2142

**Description:** Cell line NK-92 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Natural killer cell lymphoblastic leukemia/lymphoma

**Defining Citation:** PMID:8152260, PMID:9118301, PMID:9573023, PMID:10365666, PMID:10803505, PMID:11454312, PMID:12850795, PMID:16827800, PMID:18424763, PMID:19194464, PMID:20454443, PMID:21052088, PMID:21570725, PMID:25586472, PMID:26559813, PMID:30054012, PMID:31126350, PMID:31160637, PMID:34349345, PMID:36610812

**Comments:** Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support., Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing., Characteristics: Does not express FCGR3A/CD16., Characteristics: IL2 dependent., Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing. Also being developed for cellular adoptive immunotherapy for cancers and viral infections., Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Group: Patented cell line.

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** NK-92

**Synonyms:** NK92, Natural Killer-92, NK-92.05, Neukoplast, aNK

**Cross References:** BTO:BTO_0003287, CLO:CLO_0008177, EFO:EFO_0022517, AddexBio:C0003026/NA, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CRL-2407, BCRC:60414, BioSample:SAMN03471836, CCRID:4201HUM-CCTCC00052, CCTCC:GDC0052, Cell_Model_Passport:SIDM01143, Cosmic:1534874, Cosmic:1542071, Cosmic:2025326, Cosmic:2390215, Cosmic:2785204, DSMZ:ACC-488, DSMZCellDive:ACC-488, GEO:GSM472001, IPD-IMGT/HLA:13674, Lonza:1093, Wikidata:Q17149636

**ID:** CVCL_2142

**Record Creation Time:** 20220427T221344+0000

**Record Last Update:** 20260809T002423+0000

## Ratings and Alerts

No rating or validation information has been found for NK-92.

Warning: Discontinued: ATCC; PTA-6670
Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support., Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing., Characteristics: Does not express FCGR3A/CD16., Characteristics: IL2 dependent., Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing. Also being developed for cellular adoptive immunotherapy for cancers and viral infections., Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Group: Patented cell line. Warning: Discontinued: BCRC; 60414
Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support., Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing., Characteristics: Does not express FCGR3A/CD16., Characteristics: IL2 dependent., Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing. Also being developed for cellular adoptive immunotherapy for cancers and viral infections., Population: Caucasian., Part of: LL-100

blood cancer cell line panel., Group: Patented cell line.

## Data and Source Information

**Source:** Cellosaurus

## Usage and Citation Metrics

We found 422 mentions in open access literature.

**Listed below are recent publications.** The full list is available at dkNET .


Munoz MA, et al. (2026) NK cell dysfunction and interferon-? production underlie autoinflammation in mevalonate kinase deficiency. Immunity, 59(6), 1726.

Huo Y, et al. (2026) FOSL1 Orchestrates Epigenetic Reprogramming of Anaplastic Thyroid Cancer and Suppresses NK Cell-Mediated Antitumor Immunity. Cancer research, 86(9), 2184.

B?dzi?ska A, et al. (2026) The p53 tumor suppressor modulates the expression of proteins that control natural killer cell activity. Cell communication and signaling : CCS, 24(1).

Hu X, et al. (2026) Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. Cell reports, 45(2), 116882.

Kim D, et al. (2026) Bioprinted Tumor Microenvironment Models Reveal Immune Evasion and Guide CAR-NK Therapeutic Strategies. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(36), e21188.

Ianevski A, et al. (2026) Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery. Cancer research, 86(2), 295.

Zhou J, et al. (2026) Orosomucoid 2 promotes colorectal cancer liver metastasis by suppressing natural killer cell-mediated antitumor immunity by remodeling the serine and one-carbon metabolism pathway. Molecular cancer, 25(1).

Calescibetta A, et al. (2026) Combining lenalidomide with IL-2 family of cytokines enhances activating receptor and perforin/granzyme expression in NK cells. PloS one, 21(3), e0344471.

Tao G, et al. (2026) Radiation-induced MYB reduction unleashes TIM-3 expression in NK cells to attenuate antitumor immunity in colorectal cancer. Journal of translational medicine, 24(1).

Ghaffari S, et al. (2026) A fully human pan VL9 HLA-E TCRm antibody enables functional dissection of HLA-E biology and checkpoint signaling. iScience, 29(5), 115669.

Zhou Y, et al. (2025) Chronic ER Stress Triggers Cell-Surface Chaperones as the Therapeutic Targets of CAR Cells in Acute Myeloid Leukemia. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e11573.

Stransky N, et al. (2025) Chimeric antigen receptor NK-92 cell function is modulated by HLA class I expression of target cells. iScience, 28(5), 112523.

Cai HM, et al. (2025) DDX3X mutation and Epstein-Barr virus cooperate to induce R-loop-dependent oncogenesis. Cell reports, 44(9), 116237.

Gao T, et al. (2025) Molecular basis of ?2 integrin activation by talin unveils subunit-specific mechanisms of integrin signaling. Cell reports, 44(5), 115607.

Phung SK, et al. (2025) A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer. Cancer immunology research, 13(2), 258.

Decalf J, et al. (2025) Effectorless Fc-fusion improves FLT3L drug-like properties for cancer immunotherapy combinations. EBioMedicine, 118, 105822.

Hai Y, et al. (2025) An immunometabolic prodrug strategy overcomes DHODH inhibitor resistance in refractory melanoma. Journal of experimental & clinical cancer research : CR, 44(1), 306.

Ning K, et al. (2025) Non-destructive in situ monitoring of structural changes of 3D tumor spheroids during the formation, migration, and fusion process. eLife, 13.

Maskalenko NA, et al. (2025) The Fc?RIIIA (CD16) L48-H/R Polymorphism Enhances NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity by Promoting Serial Killing. Cancer immunology research, 13(3), 417.

B?dzi?ska A, et al. (2025) The puzzling regulation of the interferon signaling system by the p53 tumor suppressor protein. Cellular and molecular life sciences : CMLS, 82(1), 233.